Read by QxMD icon Read

Therapeutic Delivery

Martin Oselkin, Neda I Sedora-Roman, Bryan A Pukenas, David Kung, Robert W Hurst
AIM: Super absorbent polyvinyl alcohol-sodium acrylate copolymer microspheres, Quadrasphere microspheres (QSM), are commonly used for drug-eluting bead therapy, however, the literature only reports its use with small molecule chemotherapeutics. This study evaluates the loading and elution characteristics of bevacizumab-loaded QSM. METHODS & RESULTS: A single vial of QSM was reconstituted with 200 mg of bevacizumab. Drug concentration was determined by ELISA immunoassay...
July 27, 2017: Therapeutic Delivery
Jillian Frieder, Dario Kivelevitch, Alan Menter
Psoriasis is a common chronic immune-mediated skin disease which has a significant impact on patients' quality of life, and is associated with numerous comorbidities (i.e., psoriatic arthritis, Crohn's disease and cardiovascular disease). A greater understanding of its immunopathogenesis has guided the development of novel, more targeted therapies. Nonetheless, traditional treatment with topical agents, phototherapy and systemic medications is used in the management of the majority of psoriasis patients. Mainstay topical treatments include corticosteroids and vitamin D derivatives...
June 29, 2017: Therapeutic Delivery
Joseph M Caster, Andrew Z Wang
Chemoradiotherapy (CRT) plays a key role in the curative treatment of many human cancers. The full utility of this paradigm is often restricted by limitations of conventional drug delivery. Nanotherapeutics have demonstrated great potential to overcome many of these issues. The potential benefits of nanotherapeutics in CRT include improved therapeutic efficacy, decreased toxicity, enhanced real-time in vivo tumor imaging, and the translation of novel small molecule drugs or nucleic acid therapies. Additionally, nanomedicines and radiation therapy exert distinct and complementary effects on the tumor microenvironment which can further enhance therapeutic efficacy compared with either modality alone...
August 2017: Therapeutic Delivery
Louise Rosenmayr-Templeton
No abstract text is available yet for this article.
August 2017: Therapeutic Delivery
Anthony S Ham, Robert W Buckheit
Despite a long history of use for rectal and vaginal drug delivery, the current worldwide market for suppositories is limited primarily due to a lack of user acceptability. Therefore, virtually no rational pharmaceutical development of antiviral suppositories has been performed. However, suppositories offer several advantages over other antiviral dosage forms. Current suppository designs have integrated active pharmaceutical ingredients into existing formulation designs without optimization. As such, emerging suppository development has been focused on improving upon the existing classical design to enhance drug delivery and is poised to open suppository drug delivery to a broader range of drugs, including antiretroviral products...
August 2017: Therapeutic Delivery
Maren Preis, Jessica M Rosenholm
No abstract text is available yet for this article.
August 2017: Therapeutic Delivery
Chulhun Park, Nilesh M Meghani, Hardik H Amin, Van Hong Nguyen, Beom-Jin Lee
Pharmaceutical dosage forms address diverse key components but satisfying unmet patient needs to enhance patient adherence is a major challenge. The desired design of patient-centered drug products should be based on characteristics of various components, such as patients, disease, routes of administration, drug delivery technologies and active pharmaceutical ingredients. Understanding of targeting patients and their physiological and biological environments is pivotal for developing suitable patient-centered drug products...
August 2017: Therapeutic Delivery
Ryan F Donnelly
No abstract text is available yet for this article.
August 2017: Therapeutic Delivery
Desiree Van Haute, Jacob M Berlin
The field of nanomedicine has received much attention for its potential to allow for targeted identification and treatment of tumors, while sparing healthy tissue. This promise has yet to be clinically realized; instead nanomedicine has translated into clinical benefit via formulations that improve the pharmacokinetics and toxicity profiles of toxic chemotherapeutic agents. In this perspective, we highlight that several of the defining strategies for using nanoparticles intravenously to target solid tumors have limited supporting data in animal studies...
August 2017: Therapeutic Delivery
Yvette Pötzinger, Dana Kralisch, Dagmar Fischer
Although bacterial nanocellulose (BNC), a natural nanostructured biopolymer network, offers unique material characteristics, the number of drug-loaded BNC-based carriers in clinical trials or on the market is still low. This report provides an overview of aspects still limiting the broad application of BNC as drug-delivery system and the challenges for its future applications. Continuous large-scale production, storability, the loading and controlled release of critical drugs, for example, with high molar mass or highly lipophilic character as well as the formulation of long-term release systems will be highlighted...
August 2017: Therapeutic Delivery
David Waite, Yujing Wang, David Jones, Alan Stitt, Thakur Raghu Raj Singh
Drug delivery to the posterior segment via the periocular route is a promising route for delivery of a range of formulations. In this review, we have highlighted the challenges and opportunities of posterior segment drug delivery via the periocular route. Consequently, we have discussed different types of periocular routes, physiological barriers that limit effective drug delivery, practical challenges regarding patient compliance and acceptability and recent advances in developing innovative strategies to enhance periocular drug delivery...
July 2017: Therapeutic Delivery
Zibiao Li
No abstract text is available yet for this article.
July 2017: Therapeutic Delivery
Vivek Agrahari
No abstract text is available yet for this article.
July 2017: Therapeutic Delivery
Fabio Sonvico, Francesca Zimetti, Adriana Raffin Pohlmann, Sílvia Stanisçuaski Guterres
Statins are used for the primary and secondary prevention of cardiovascular disease by inhibiting cholesterol synthesis in the liver. Statins have also noncholesterol-related effects, called pleiotropic effects, which arise from statins' anti-inflammatory, immunomodulatory and antioxidant properties. These effects are especially attractive for the treatment of various brain diseases ranging from stroke to neurodegenerative diseases. Still, low brain concentrations after oral drug administration hinder the clinical application of statins in these pathologies...
July 2017: Therapeutic Delivery
Mudra Saurabh Kapoor, Shruti GuhaSarkar, Rinti Banerjee
Skin is the outermost and largest protective covering of the body. The uppermost layer of the skin, stratum corneum also called the horny layer is composed of keratin-filled cells covered by a lipid matrix which shields the skin from physical and chemical entrants. The lipid lamellar structure comprises of ceramides, cholesterol, fatty acids and proteins. Chemical enhancers that mimic the lamellar chemistry, reversibly fluidize the latter can be utilized for enhancing transport of cargo across the epidermis into the dermis...
July 2017: Therapeutic Delivery
Giuseppe, Serena Riela, Rawil F Fakhrullin
Clays for drug delivery have been used from ancient time due to the large availability of clay minerals and their unprecedented properties. The empirical use of nanoclays from the past is converted in a stimulating scientific task aimed at building up nanoarchitectonic vehicles for drug delivery in a targeted and stimuli-responsive fashion. Here the historical aspects are discussed; next the modern examples of applications of different clay-based materials are discussed. A special focus is given to halloysite clay nanotubes, which are an emerging and very promising nanomaterial for drug-delivery purposes due to its special morphology and unique chemical properties...
July 2017: Therapeutic Delivery
Iain Simpson
This Industry Update covers the period from 1 through 30 April 2017, and is based on information sourced from company press releases, scientific literature, patents and various news websites. Biogen expanded its portfolio of developmental drugs targeting neurological diseases by licensing a drug from Bristol-Myers Squibb which is currently under investigation for the treatment of progressive supranuclear palsy. Takeda announced a deal with NuBiyota focused on developing treatments for gastrointestinal disorders, based on the manipulation of microbes living in the gut...
July 2017: Therapeutic Delivery
Kambham Venkateswarlu, Manyam Nirosha, Budideti Kishore Kumar Reddy, Badithala Siva Sai Kiran
AIM: In the present investigation, oral dissolving/dispersible/disintegrating tablets (ODTs) of clopidogrel were designed with a view to enhance the bioavailability and patient compliance by two different methods, namely, direct compression and effervescent methods using directly compressible excipient and treated agar (TAG). MATERIALS & METHODS: In the direct compression method, TAG was used as a disintegrant and another method used a mixture of sodium bicarbonate and tartaric acid along with TAG as disintegrants...
July 2017: Therapeutic Delivery
Joël Richard
Therapeutic peptides have become very successful drugs due to their specificity, potency and low toxicity, but they show challenges for their delivery, due to their short half-life and rapid plasma clearance. For these reasons, peptides are usually administered using injectable sustained-release formulations. Oral peptide route is highly compelling from a patient and commercial point of view. However, poor peptide stability and low permeability across the intestinal epithelium still make it very challenging to effectively deliver peptides by the oral route...
July 2017: Therapeutic Delivery
Stephen P Newman
Pulmonary drug delivery is relatively complex because the respiratory tract has evolved defense mechanisms to keep inhaled drug particles out of the lungs and to remove or inactivate them once deposited. In addition to these mechanical, chemical and immunological barriers, pulmonary drug delivery is adversely affected by the behavioral barriers of poor adherence and poor inhaler technique. Strategies to mitigate the effects of these barriers include use of inhaler devices and formulations that deliver drug to the lungs efficiently, appropriate inhaler technique and improved education of patients...
July 2017: Therapeutic Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"